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ABSRACT 
 Objectives: The objective of this study is to assess the impact of medication 
synchronization (med sync) on medication adherence for three drug classes under the CMS Star 
Rating system i.e. oral diabetes, hypertension and cholesterol. 
 Methods: A quasi-experimental pre-post study design was employed using pharmacy 
prescription fill data from various independent community pharmacies located in different 
regions of Mississippi. Using Proportion of Days Covered (PDC), medication adherence before 
and after the med sync was calculated. Total study period of one year for each patient including 
six months of pre-period and post-period was used for the analysis. Descriptive statistics were 
calculated. Wilcoxon-Signed Rank test was performed to compare the pre-period adherence to 
post-period adherence. Proportion of adherent patients before and after the med sync were also 
compared using McNemar’s Exact Test. Using the obtained 2x2 contingency table odds ratio of 
being adherent in post-period as compared to pre-period was calculated. 
 Results: A total of 56, 89 and 77 patients were found to meet the inclusion/exclusion 
criteria in diabetes, hypertension and cholesterol drug categories, respectively. The approximate 
average age of the patients for the three drug classes was as follows: diabetes 66 years (23-87 
years, ± 11.03), hypertension: 70 years (41-101 years, ± 11.53) and cholesterol: 67 years (40-100 
years, ± 11.85). Majority of the study sample belonged to 60-80 years of age and had PDC 
values ranging from 90-100 in both pre-period and post-period for all the three drug classes. 
Average post-period PDC (0.99) was higher than average pre-period PDC (0.94) and was also 
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statistically different from each other for all the three drug classes. Increase in the proportion of 
adherent patients from pre-period to post-period was witnessed for the three drug classes i.e., 
diabetes (91.07% to 100%), hypertension (89.89% to 98.88%) and cholesterol (90.91% to 
98.70%). However this increase was only statistically significant for the hypertension drug class 
(p=0.0215). Also, patients in post-period had higher odds of being adherent in post-period as 
compared to pre-period for all the three drug classes. 
 Conclusions: The results indicated that after being enrolled in med sync, medication 
adherence generally improves.
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 INTRODUCTION 
The problem of non-adherence 
Medication non-adherence, or the failure to take medications as prescribed, is one of the 
most significant factors limiting the effectiveness of medications in practice.1 Almost two-thirds 
of Americans are non-adherent to medications2 and specifically, 50% of patients taking chronic 
medications are non-adherent.1 Hospitalizations, morbidity and mortality are some of  the 
consequences associated with medication non-adherence. 
The causes of non-adherence are dynamic and varies by individual. Non-adherence can 
be related to age, culture, social background, values, and attitudes. Disease-related factors such 
side effects of the medication, treatment duration, frequency of expected intake, and treatment 
complexity also impacts patients’ medication taking behaviors. Some external factors 
contributing to non-adherence are the relationship between the patient and the physician or the 
nurse, support from the family, health care personnel, and friends and also the amount of health 
education a patient has.4,5 Financial factors contributing to non-adherence include higher co-pay 
and co-insurances.6 This necessitates the need to develop an intervention which is modifiable and 
can be tailored for individual patients.1 
Due to the various causes of non-adherence, there is no one solution to addressing this 
issue.  Additionally, some existing interventions that demand multiple visits to the pharmacy by 
either the patient or caregiver not only causes inconvenience to the patient but also interrupts the 
workflow of the pharmacist. Such interruptions can lead to declines in medication dispensing 
rates and gaps in the medication therapy further causing non-adherence.7 
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Addressing adherence with medication synchronization 
An ideal adherence intervention should be one that addresses the multidimensional and 
dynamic nature of non-adherence. It should be able to improve access to care, be more 
convenient, educate the patients, and provide constant reminders. It should also help the patient 
monitor their own improvement and help them engage in mutual problem solving.1 
One of the most recent proposed methods to address the above-mentioned issues in non-
adherence is medication synchronization (med sync).  Med sync is essentially refill 
synchronization. It is a process by which multiple chronic medications are refilled at the same 
time one day of the month instead of throughout the month.1  
With med sync, the focus of the pharmacy staff changes from filling the prescription 
reactively upon the sudden request of the patient, to a more organized, synchronized and active 
pick-up or delivery of the prescription. This is a patient centric pharmacy care model, different 
from the traditional drug centric model.8 This patient centric care model, emphasizes the 
preferences, values and needs of the patient. It means that the patient will participate actively in 
the shared decision making process.9 
Study significance 
Adherence plays a crucial role in the Centers for Medicare and Medicaid Services’ 
(CMS) Star Rating system which is designed to assist Medicare beneficiaries in plan selection. 
Among the five measures used by CMS and Pharmacy Quality Alliance (PQA) for calculating 
the Star Rating, three of them are related to the medication adherence, therefore making 
adherence improvement a high priority.7 With the development of the Medicare Star Rating 
System and the increase of commercial Part D plans, it becomes crucial to monitor the adherence 
subsequent health outcomes.3 This implies that more empirical research is required to measure 
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adherence as a result of synchronization. Limited research has examined this phenomenon as 
only two studies have examined the impact of synchronization on adherence, using a matched 
cohort design and quasi-experimental study in which study patients were matched with control 
patients.1,10 The current study had a pre-post research design, to strengthen the adherence 
literature related to medication synchronization. 
Study objectives 
The specific objectives of this study were to: 
Assess the impact of medication synchronization on medication adherence for the following 
CMS Star Rating system drug classes: 
1. Oral diabetes medications which include biguanides, sulfonylureas,  thiazolidinediones, 
DPP-IV inhibitors, and meglitinides; 
2. Hypertension medications which include renin-angiotensin system antagonists (RASAs) 
which includes angiotensin converting enzyme inhibitors (ACEs), angiotensin receptor 
blockers (ARBs); and  
3. Cholesterol medications which includes statins.
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LITERATURE REVIEW 
Defining medication adherence 
Before discussing how non-adherence might be addressed with med sync, it is important 
to first define medication adherence, and differentiate it from “compliance” and “persistence”.  
Medication compliance is defined as “the extent to which a patient acts in accordance with the 
prescribed interval, and dose of a dosing regimen” and can be demonstrated when a patient’s 
prescriptions are dispensed on a regular basis as prescribed by the physician. Whereas, 
persistence is defined as “the duration of time from initiation to discontinuation of therapy” and 
is a continuous variable represented by the total number of days for which the therapy was 
accessible. These terms sound similar but they are different because the clinical outcomes of the 
therapy depends upon both the medication as well as the duration for which the medications are 
consumed.11 The difference between adherence and compliance is that compliance is considered 
to be passively following the instructions given by the physician whereas adherence occurs when 
both the patient and physician have mutually agreed upon the medication regimen.12 
The problem of non-adherence 
Looking at the case of chronic disease, non-adherence is a critical issue as almost 133 
million people are suffering from at least one chronic disease in the US.  Fifty percent of patients 
do not take their medicines properly, and 31% of them never get their original prescription 
filled.13 Non-adherence can lead to problems such as medication ineffectiveness, increases in 
healthcare spending, hospitalizations, and emergency room (ER) visits.12 It has been reported 
that non-adherence causes almost 125,000 deaths in the US and incurs a cost of $177 billion 
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annually.14  Chronic diseases such as hypertension, diabetes, hypercholesterolemia and 
congestive heart failure (CHF) are among the most prevalent, costly, or both; therefore 
addressing medication adherence related to these disease states becomes critical.13 
 With regard to persistence, adherence achieved in chronic disease states have been 
reported to worsen, dropping after the initial 6 months of the therapy itself. In clinical trials, 
adherence tends to be more ideal than world scenarios, even then, adherence achieved in chronic 
illness patients is low, ranging from 43 to 78%. The consequences of non-adherence are 
significant, including exacerbation of the disease, higher mortality, increased healthcare costs, 
and increased hospitalizations.  Thirty-three percent to 69% of hospitalizations in the US are 
attributed to non-adherence and incur $100 billion annually.12 
The causes of non-adherence 
The six patterns of medication taking behavior found among patients with chronic 
illnesses helps to explain the prevalence of non-adherence. One-sixth of patients attain near 
perfect adherence; one-sixth consume almost all the doses but at irregular times, one-sixth 
occasionally skip single day doses and take doses at irregular times, one-sixth take drug holidays 
about 3-4 times in annually while skipping doses occasionally, one-sixth take drug holidays 
every month with and skip medications frequently, and one-sixth consume few or no doses while 
trying to appear as though they are adherent.12 
The causes of non-adherence are many and varied. The World Health Organization 
(WHO) has classified five factors as major underlying causes for non-adherence. The first factor 
includes individual characteristics such as physical condition, cognitive abilities, and 
demographics such as age, gender and race. The second factor includes a patient’s medical 
condition including asymptomatic condition and comorbidities. The third factor includes the 
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health system in which the patient lives and the type of care the patient receives. The fourth 
factor includes the complexity of therapeutic regimen and fifth factor includes all the 
socioeconomic barriers patient faces. Osterberg goes on to note that non-adherence factors 
include complicated therapeutic regimens, improper explanation of benefits and side effects of 
the medication, lack of concordance with patient lifestyles, and poor patient-physician 
relationships.12 
Outcomes and costs of non-adherence in chronic disease 
As previously discussed, chronic diseases are victim to the issue non-adherence the most. 
Considering the example of diabetes mellitus, non-adherence is one of the most prevalent issues 
leading to unfavorable outcomes. In a study, the unadjusted analysis states that diabetic non-
adherent patients have higher percentage of having all cause hospitalization (23.2% vs 19.2%, p 
< .001) and all-cause mortality (5.9% vs 4.0%, p < .001) as compared to adherent patients. It has 
also been observed that less than half of the patients consuming statin medications remained 
adherent to the therapy after 12 months of starting the therapy. Results of a multivariable 
analysis of this study was in agreement with the results above. Increased risk for all cause 
hospitalization (OR, 1.58; 95% CI, 1.38-1.81; p < .001) and all-cause-mortality (OR, 1.81; 95% 
CI, 1.46-2.23; p < .001) was observed. Cumulative results were consistent with the results of the 
individual categories such as oral hypoglycemic, antihypertensive and statin medications. It was 
found that with a 25% rise in adherence of antihypertensive medications, an associated decrease 
of -1.0mm Hg and -1.2 mm Hg in systolic and diastolic blood pressure was observed. Similarly, 
with a 25% increase adherence to oral hypoglycemic and statins a reduction of -0.05% and -
3.8mg/dL was observed in HbA1c and LDL-C levels respectively. In this study combined 
reduction in the magnitude of hospitalization and mortality was higher than what was anticipated 
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given the changes in the intermediate measure. This indicates that adherence might also be 
related to self-care behaviors that may or may not be directly related to the final outcomes. 
Looking at the importance and consequences of non-adherence, we can conclude that medication 
adherence should be assessed by the healthcare providers on a regular basis.15 
The systematic literature also indicates that due to non-adherence to oral hypoglycemic 
medications, only 43% of the diabetic patients have glycosylated hemoglobin levels under 7% as 
recommended by American Diabetes Association. For hypoglycemic agents, a range of 13% to 
64% was found for total number of non-adherent patients.16 Lower levels of Medication 
Possession Ratio (MPR), a measure of medication adherence was also found to be correlated 
with higher costs. MPR can be defined as “Ratio of the number of days’ supply dispensed to a 
patient, divided by the number of days in the cohort period, typically a year”. MPR of 60% is 
found to be associated with mean total cost of $8,699. Whereas, a 10% increase in the MPR can 
be correlated to reduction of 8.6% in total annual healthcare costs. It has been noted that HbA1c 
levels lesser than 8% and HbA1c greater than 10 incurred a cost of $4,475 and $8,088, 
respectively.14,16 Financially, incident cases are more expensive than prevalent cases and 
gestational diabetes cases are more expensive than type-2 diabetes cases.16 These findings 
strongly emphasizes on the importance of medication adherence with respect to both healthcare 
cost and healthcare utilization. 
Bolstering the above findings, another study focusing on the causal link between 
medication adherence and health care use and cost for four vascular diseases (hypertension, 
diabetes, dyslipidemia, and congestive heart failure (CHF)) was conducted. Results indicated that 
although increase in medication adherence causes an in increase total pharmacy costs, it helps in 
saving a substantial amount of money by reducing overall expenditure in hospitalizations 
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particularly linked with inpatient hospital days and ER visits. Hospitalizations and ER visits are 
of priority as they are the key drivers of healthcare costs. Results indicate that adherence in 
dyslipidemia and CHF can be associated with fewer inpatient hospital days, ranging from 1.18 
fewer days to 5.72 fewer days respectively. The average benefit-cost ratio due to medication 
adherence for CHF, hypertension, diabetes and dyslipidemia can be given as 8.4:1, 10.1:1, 6.7:1 
and 3.1:1 respectively. Financial gains resulting from better adherence truly justifies adopting 
adherence management programs that can lead to considerable medical savings. Results also 
recommend the use of pharmacist-led patient counseling as a promising intervention to improve 
adherence at lower expenses.13 
Another study evaluating the impact of adherence on healthcare utilization and cost for 
diabetes, hypertension, hypercholesterolemia and CHF was performed. For diabetes and 
hypercholesterolemia, low disease-related medical costs were found to be correlated with higher 
levels of medication adherence and these higher levels were associated with significantly fewer 
hospitalizations. For hypertension, hypercholesterolemia and diabetes, pharmacy cost was offset 
for all-cause medical cost at relatively higher levels of medication adherence. It can be inferred 
that benefits gained due to increased prescription drugs (due to improved adherence) is worth the 
added cost.17 
Another study was conducted focusing on finding the association between medication 
adherence and utilization for acute healthcare services. Results of logistic regression analyses 
suggested that adherence was a significant predictor of all-cause hospitalizations and ER visits. It 
was observed that chances of all-cause hospitalization and ER visits among the adherent patients 
were 40% less in patients with diabetes, 44% less in patients with hypercholesterolemia and 35% 
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less in patients with hypertension. These findings imply that policy makers should focus on 
interventions that can improve adherence leading to other benefits.18 
Addressing non-adherence 
Considering the importance of adherence in a multidimensional aspect, it becomes crucial 
to employ interventions that can improve adherence which can lead to reduction in total 
healthcare cost. One of the most crucial reasons to focus on adherence comes from the Centers of 
Medicare and Medicaid Services (CMS). CMS evaluates Medicare Part D plans on the basis of 
Star Rating system ranging from one to five stars. Star Rating consist of four sections, one of 
which is categorized as pricing and patient safety. This section consists of measures evaluating 
medication adherence for oral diabetes agents, hypertension agents and cholesterol agents. Star 
Rating are useful in making quality based payments to Medicare Advantage Plans (MA-PDs) 
and selling benefits to prescription drug plans (PDPs).19 
As stated in a Chain Drug Review article, MA-PDs cannot achieve the five-Star Rating 
without active and effective participation from community pharmacies that create quality patient 
outcomes.19 In agreement, the 2012 WHO report stated that interventions aiming at improving 
medication adherence are more capable of improving health of people than any other medical 
intervention.19 It has been reported that that five out of every six pharmacist directed adherence 
interventions can improve the adherence of patients ranging from 7% to 27%. Pharmacist-led 
interventions have approximately 83% successfully adherent patients as compared to 67% 
adherent patients in electronic interventions with no involvement of humans, 38% adherent 
patients in phone calls lead interventions and 38% adherent patients  involved in clinic programs 
making the role of pharmacists important in the adherence management program.1 Interventions 
that can help to reduce wait times and improve the communication between physicians and 
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patients could be more beneficial. Patients who often miss their appointments are those who may 
require assistance the most to become adherent. They can be helped by providing increased 
information, motivation and imparting behavioral skills.12,20 
Considering the dynamic and multidimensional nature of medication adherence, 
especially in chronic diseases as stated above, medication synchronization (med sync) may be a 
solution to managing medication adherence. Med sync is a process of coordinating multiple 
chronic medications of a patient to be picked-up or delivered on one day each month.1   There 
are several med sync programs available on the market such Elite Care, MedSync, 
SyncYourMeds, HealthyPackRx, RxSync, SimplifyMyMeds, TimeMyMeds and the 
Appointment Based Model (ABM).   
Medication synchronization – how it works 
One of the major steps of the med sync process is to identify ideal patients for the 
program.  Patients using multiple chronic medications and making multiple visits to the 
pharmacy in a month are the best fit for the program. Multiple monthly visits made by the patient 
to the pharmacy should be taken into consideration. Patients who visit the pharmacy multiple 
times per month to maintain their social network may not be good candidate for med sync.21 
 Once a patient is deemed a good candidate for med sync, the anchor drug must be 
identified. An anchor drug is defined as the drug around which the first synchronization date is 
identified.1,21 The cost of the drug, amount of co-pay and out-of-pocket costs are among the 
various deciding factors for the anchor drug selection.7 
Selection of the chronic drugs to be synchronized is another important component in the 
initiation of the program. Not all the chronic drugs are eligible for the inclusion in the program. 
Chronic drugs such as sedative hypnotics, anxiolytics and analgesics are not recommended for 
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the enrollment in the synchronization process. Other chronic medications inappropriate for the 
synchronization includes those with non-standardized doses such as insulin, creams, eye drops 
and inhalers and drugs with varying cycles such as bisphosphonates, oral contraceptives and 
vitamin D. Pre-written Schedule II prescriptions and medications in unbreakable packaging are 
not good candidates for synchronization. Drugs treating hypertension, diabetes, and 
hypercholesterolemia are among the suitable candidates.7 
While selecting first synchronization date, the pharmacist should provide patients with 
short fills and long fills depending upon the doses remaining on the patient’s current 
prescriptions. Short fills are for a less than usual supply whereas long fills are dispensing 
medication more than the typical supply.8 This avoids disruption in the continuity of therapy.1 
Alternatively, the pharmacist or technician may contact the physician to reauthorize all new 
refills for a patient for 28 or 30 days.  Once the drugs to be synchronized are decided, they are 
documented in a pre-appointment call sheet. 
A week before the appointment day the pharmacist or technician calls the patient to check 
about changes in the medication regimen, if any. This call differentiates med sync from other 
automatic refill programs as it is an opportunity to gain meaningful information about the patient 
which is not possible during an automated call.8 Additionally, it develops a sense of being cared 
for in the patient’s mind and the perception that a complete health system is  attempting to help 
them to have a healthier life.8  Additionally, the pharmacist or technician identifies any problems 
with medication adherence and any medical issues of concern.  Once the call is complete, the 
pharmacist or technician adjudicates and processes the prescriptions in preparation for filling the 
prescriptions.  Any insurance related issues are also resolved at this time.  
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Three days before the appointment day, the pharmacist or technician fills the prescription 
for subsequent pick-up or delivery. The day before the prescription is due or even that day, 
depending upon the preference of the patient, the medication is either collected by them or is 
delivered to them by the courier (or mail service if delivered earlier).22 In some med sync 
programs, patients who fail to pick-up their medication on the pick-up day are contacted by the 
pharmacist.21 
Physicians play a critical role throughout the process. It is the responsibility of the 
pharmacist to inform the physician if their patients enroll in med sync. A formal letter should be 
mailed to the physician with a request to refill the synchronized medications.1,7 Communication 
with the physician helps the physician gain additional information about the patient who is 
enrolled in med sync. 
Benefits of medication synchronization 
Benefits to patients. Med sync is argued to be beneficial in improving the overall 
adherence of a patient in several ways. Fewer number of pharmacy visits may lead to better 
medication adherence and promote continuity of care, thereby improving access to care.1 Unlike 
traditional, reactive, prescription filling, med sync prescriptions get filled within a week of the 
pick-up or delivery date leading to reduction in medication gaps and unavailability of medicines. 
By the time patient reaches the pharmacy to pick-up their medication their insurance has already 
been processed resulting in more convenience.1  In some med sync programs, the monthly 
appointment with the pharmacist gives the pharmacist an opportunity to clarify, modify, and 
enhance the patient’s medication therapy leading to a reduction in possible medication errors.1 
Monthly phone calls (and appointments, if used) helps the pharmacist educate the patient and 
involve them in solving drug-related and adherence problems related to lack of affordability, 
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physical impairment, low health literacy and shortage of social support. Synchronization 
simplifies the medication regimen and provides constant progress updates and feedback to the 
patient and the patient’s physician.1,3  
Med sync helps manage medications with greater therapeutic complexity, leading to 
improved outcomes.1 Synchronization takes care of the preference of the patient with regard to 
the payment, delivery and mode of contact as well. Patients have the choice to either pick up 
their medication or receive it by mail or courier. They can pay for the medication by either a 
single monthly payment or have the option to split it up in several monthly installments. Patients 
can be contacted by cell phone, home phone or even email.1 
Benefits to pharmacists. Med sync allows the pharmacist to step out from behind the 
counter and provide patients with the healthcare and clinical services they require. Better 
management of pharmacy work flow is an advantage as everything taking place at the pharmacy 
is pre-planned and proactive.  The frequency of phone calls is reduced as the system is more 
structured, yielding substantial time savings and more organized staff.3 It improves the overall 
business in the pharmacy by increasing the prescription revenue and gives an opportunity to 
provide Medication Therapy Management (MTM) services and additional clinical services like 
immunizations and flu shots.1 Med sync also reduces the  total number of random visits made by 
the patients, which helps in managing the  disorder in the pharmacy and also helps to reduce the 
stress levels of the pharmacist working there.8  To summarize, med sync promotes the 
achievement of overall operational efficiency of the pharmacy.21 
Med sync allows the pharmacist to better perform in their role as a healthcare provider. 
They can offer suggestions regarding over-the-counter medications and guide the patient towards 
a better diet, lifestyle changes and needed home equipment.3 It also allows the pharmacist to 
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provide Medication Therapy Management (MTM) services to the patient, and possibly be 
reimbursed for these services. As an added advantage, the outcome data collected in this process 
are often used to incentivize pharmacists which motivates pharmacists to perform better.8 
In terms of business, med sync can give fruitful returns for the invested labor. Findings 
state that prescription revenue has gone up by 29% for patients who are associated with the 
pharmacy for a year or more by using Elite Care which is a med sync program offered by Red 
Cross pharmacy.3 
Benefits to physicians. Physician-pharmacist communication that occurs when enrolling 
patients for med sync serves as opportunity to educate the physician about the advantages of med 
sync and gather support from them.7 The literature suggests that physicians are pleased with med 
sync programs and improvement in medication adherence, and receiving feedback related to 
adherence.21 As stated by a pharmacist based in Colorado, with the help of med sync programs, 
pharmacists have taken the time consuming part of the physician’s job, and that physicians truly 
appreciate it.8 
Challenges of medication synchronization 
The challenges associated with med sync include identifying and enrolling patients, 
identifying anchor dates and drugs, differentiating sync patients from the non-sync patients, 
managing short-fills and long fills.2 While dispensing short fills and long fills to reach a sync 
date, the pharmacist needs to address insurance issues as well. Because all of a patient’s 
prescriptions are being dispensed on the same date, the pharmacist needs to manage and 
calculate the co-pays carefully. This can be more difficult when dealing with Medicare Part D 
patients who are moving into the donut hole21 and Medicaid patients who may have a 
prescription cap.  Pharmacists should make patients aware of the possible one-time cost 
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associated with the co-pays and out-of-pocket costs related to the short fills received just before 
the first sync date.7 
Considering that the role of pharmacist is crucial in the successful implementation and 
maintenance of med sync, pharmacists and their staff need to be constantly educated on a regular 
basis. Educational materials may include modules related to patient centered care, prescription 
synchronization techniques, maintenance of proper documentation, methods to foster mutual 
problem solving, and providing MTM services. Having improved and efficient technology might 
also results in easier implementation and scalability of med sync helping in creating and storing 
data which can be of help to prove the program’s worthiness in the future. 
Med sync research findings 
In a study conducted by a joint collaboration of the National Community Pharmacists 
Association (NCPA) and Ateb Inc., investigators measured the impact of Ateb’s Time My Meds 
synchronization program on medication adherence. They created a study group and matched it 
with a control group.  Results indicated that Time My Meds made a substantial improvement in 
the medication adherence of the patients and also helped in increasing the pharmacy’s revenue 
and total gross margin.10 
Another study was conducted by Virginia Commonwealth University (VCU) with Thrifty 
White Pharmacy, a chain of employee-owned community pharmacies.  In this study, the 
Appointment Based Medication (ABM) med sync model was used. Investigators utilized a quasi-
experimental research design while matching the study patients to the control. It resulted an 
increase in the adherence of the patients and also showed a decreased probability of non-
persistence. Specifically, it was reported that by increasing a diabetic patient’s medication 
adherence from 40-59% $4,091 can be saved per patient.3 With 25.8 million diabetic patients in 
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the US, the amount of savings could be phenomenal. This study also reflected an increased level 
of adherence among study patients as compared to the control patients. Patients enrolled in the 
med sync had adherence rates of 66.1%-75.5% as compared to the control patients with 37%- 
40.8% for initial one year. In terms of odds of adherence, study patients had 3.4-6.1 times higher 
odds of adherence compared to control.1 A follow-up study conducted for Thrifty White’s study 
displayed increased adherence with med sync program. It resulted in a significant drop in the 
cost of healthcare with patients having hypertension, diabetes and increased cholesterol levels.22 
Due to med sync’s positive results and improvement in adherence, almost 250-350 
people a week enroll in med sync at Thrifty White Pharmacy. Most of the patients enrolled in the 
study were 40 to 55 years old.  People in this age group are those who are working and have a 
busy schedule. Providing reminders for their medication can be helpful for them to maintain their 
health in their hectic life style. Overall, med sync has been successful in yielding positive results 
by improving medication adherence of patients.  This is well reflected in both patient satisfaction 
surveys as well as the talks done with the payers.22 
Summary 
These findings combined with the importance of medication adherence for the healthcare 
system makes further empirical examination of med sync an important step toward better 
medication use outcomes and lowered healthcare spending.  In fact, state legislatures are 
recognizing this importance.  For example, Missouri was one of the first states to propose a bill 
stating that pharmacies providing medication synchronization should be reimbursed for the short 
fills dispensed for the reason of synchronization.23  Continued research using alternative study 
designs are necessary for understanding the role of med sync in medication adherence 
management. 
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METHODS 
Study design 
A quasi-experimental pre-post study design was employed for this study using pharmacy 
prescription fill data from various independent community pharmacies located in different 
regions of Mississippi.  Patients were compared on the main outcome measure, medication 
adherence, before and after the medication synchronization intervention. Because this study 
employed a pre-post study design, patients served as their own control. 
A six month pre and post study period was used to measure adherence. Analyses were 
conducted separately for each of the drug classes under the CMS Five-Star Quality Rating 
System. Drug classes in the CMS Five-Star Quality Rating System include oral diabetes 
medications, hypertension medications and cholesterol medications.  
The total study period for each patient was one year, including the pre- and post-study 
period. Patients’ medication adherence was calculated for a six month period before the index 
date and a six month period after the index date. The index date was used to separate the pre- and 
post period of each patient.  Index date was defined as the first med sync date when the patient 
received his first fill of the prescription after enrollment in the med sync program. Index date 
(also termed med sync date) was agreed upon by the pharmacist and the patient, and on this date 
all prescriptions were dispensed at the same date every month. Each patient was flagged on their 
specific index date in the data indicating the start of the med sync program. This flag was used to 
separate the pre and post intervention period. The post period of six months was a part of the 
treatment period. Treatment period was defined as time beginning from the index start date 
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(ISPD) until the last day of post period or end of measurement period or until death or 
until discontinuation from the med sync program. This study received an approval from the 
Institutional Review Board (IRB) of The University of Mississippi. 
Data extraction 
Pharmacy prescription fill data was collected for the dates January 1, 2008 until the date 
investigators visited the pharmacy (hereafter called as the measurement period).  Med sync 
patients were identified until the time each patient had sufficient post period of six months so as 
to have a sufficient time frame to measure post period (post-index date) medication adherence 
for enrolled patients.  Each patient had their own index date and based upon that a unique and 
separate pre-post period. 
Sample description 
A convenience sample of independent community pharmacies practicing medication 
synchronization was used for identifying med sync patients. Selected pharmacies were situated 
in various regions of Mississippi therefore reducing the geographical bias. All med sync patients 
having a prescription fill history in the measurement period within each pharmacy and satisfying 
the inclusion and not eliminated by exclusion criteria (described below) were used for analysis. 
Table 1 outlines a convenience sample of independent community pharmacies used for 
the study. Before extracting data from the pharmacies, a Data Use Agreement (DUA) was also 
executed between each pharmacy and the University of Mississippi. All patients having a 
prescription fill history in the measurement period within each pharmacy were taken. While 
performing the analysis patients meeting the inclusion criteria and not eliminated by exclusion 
criteria (described below) were used. 
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Table 1: Convenience Sample of Pharmacies 
Store name Pharmacist contact City 
Gene Polk’s Pharmacy E. Brinson Polk, Jr. Magee 
Iuka Discount Drugs Chris Cornelison Iuka 
Thrift Drugs Marty Bigner McComb 
Tyson Drug Co Bob Lomenick Holly Springs 
 
Inclusion criteria 
 Patients were enrolled in med sync program offered by their pharmacy. Patients at least 
18 years of age were included in the study. Every patient taking prescription medications 
belonging to the following drug classes were included in the analysis: Oral diabetes medications 
which included biguanides, sulfonylureas, thiazolidinediones, DPP-IV inhibitors and 
meglitinides; hypertension medications which included renin-angiotensin system antagonists 
(RASAs), angiotensin converting enzyme inhibitors (ACEs), angiotensin receptor blockers 
(ARBs); and cholesterol medications which included statins. Patients taking these medications in 
oral dosage form, only, were included in the analysis. Patients had to have an index date in order 
to meet the requirements of a pre-post design. Patients having a continuous prescription history 
of at least 180 days (six months) before and after the index date were included in the analysis. 
Exclusion criteria 
 With regard to prescription transactions, records for insulins and incretin mimetics 
(administered by subcutaneous injection), were removed before analysis due to inability to 
synchronize refills of these medications. Patients having a continuous gap equal to or more than 
90 days during the observation period were also excluded assuming that they have discontinued 
taking the medications.  Also, patients having missing values for age or date of birth were 
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removed from the analysis. This was done in order to comply with the IRB regulations of 
including patients only with greater than or equal to 18 years of age.  
Sample size 
Wilcoxon Signed-Rank Tests was performed in order to assess any changes in 
medication adherence from the pre-period to the post-period. Sample size requirements for 
Wilcoxon Signed-Rank Tests were calculated using G*Power. According to result obtained by 
G*Power, a total sample size of 82 patients (number of pairs) was needed in order to perform a 
Wilcoxon Signed-Rank Tests with a medium effect size of 0.3 and alpha level of 0.05 to obtain 
a power of 80% assuming we use minARE as the parent distribution. When the parent 
distribution is unknown, then “minARE” is used as the parent distribution while performing the 
sample size calculations. Also, the value of effect size (0.3) was chosen for this test. It is the 
standard value used to obtain a medium effect size which can be used for sample size 
calculations for the Wilcoxon Signed-Rank Test for matched pairs.24 Considering the analysis 
was be performed separately for the three drug classes, we required 82 patients’ pairs in each of 
the drug classes for the analysis. A brief synopsis of the above sample size calculations for 
Wilcoxon Signed-Rank Test for paired data is provided in Table 2 below: 
 
 
 
 
 
 
 
24 
 
Table 2: Sample Size Calculation for Wilcoxon Signed-Rank Test for Paired 
Data 
 Alpha Power Medium 
Effect Size 
Distribution Total Sample 
Size (N= # of 
pairs) 
      
Diabetes  0.05 0.8 0.3 minARE 82 
Hypertension  0.05 0.8 0.3 minARE 82 
Cholesterol  0.05 0.8 0.3 minARE 82 
 
When assessing the study outcome, patients having a PDC greater than or equal to 80% 
were considered “adherent” and patients having a PDC less than 80% were considered “non-
adherent”. A dichotomous flag variable was created by flagging adherent patients as “1” and 
non-adherent as “0”.  The proportion of individuals who were adherent was calculated for the 
pre- and post- periods using this dichotomous flag variable. In order to assess the significance of 
the difference between two correlated proportions, McNemar’s Test was performed. G*Power 
was used for sample size calculations for this analysis test, and sample size calculations were 
calculated separately for the three CMS Star Rating system drug classes.  In order to calculate 
sample size, the value of the proportion of discordant pairs and odds ratio of being adherent in 
post period as compared to pre period in the G*Power was needed. Discordant pairs are those 
patients who are adherent in pre-period and non-adherent in post-period (“Adherent”~“Non-
Adherent”) OR those patients who are non-adherent in pre-period and adherent in post-period 
(“Non-Adherent” ~“Adherent”). Whereas, concordant pairs are those patients who are adherent 
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in pre as well as post period (“Adherent” ~“Adherent”) OR those patients who are non-
adherent in pre- as well as post-period (“Non-Adherent” ~“Non-Adherent”).  The proportion of 
discordant pairs can be calculated by the sum of the proportion of discordant pairs in pre-period 
(Ppre) and the proportion of the discordant pairs in post-period (Ppost) i.e. PD= (Ppost +Ppre). 
Considering data was not collected at the time of sample size calculations, the values of the 
proportion of discordant pairs in pre-period (Ppre) and post-period (Ppost) were unknown, the 
following approximation formula was used to calculate proportion of discordant pairs (PD): Pt 
(1-Ps) + Ps (1-Pt). Where, Pt is the proportion of adherent patients in post-period and Ps is the 
proportion of adherent patients in pre-period. This provided an estimate of the PD for the sample 
size calculation. The odds ratio was calculated by dividing the proportion of discordant pairs in 
post-period by the proportion of discordant pairs in pre-period, i.e., Ppost/Ppre. It is proved that, 
Pt=Ps is equivalent to Ppost=Ppre, therefore the odds ratio was calculated by Pt/Ps.
25 
 Oral medications including biguanides, sulfonylureas, thiazolidinediones, DPP-IV 
inhibitors, and meglitinides. According to the performance scores calculated on Mississippi 
Medicare data for the year 2007, approximately 18.20%, 33.3% and 41.5% patients (18 
years and older) were found to be adherent (meeting PDC threshold of 80%) to oral diabetes 
medications (Thiazolidinediones, Biguanides and Sulfonylureas respectively). According to 
guidelines given by the CMS Star Rating system (Prescription Drug (Part D) Plans, i.e., 
PDP) a pharmacy needs to have a percentage of adherent patients between  ≥ 79% and < 
82% in order to achieve 3 stars in the CMS Star Rating system. For the purpose of this 
analysis the proportion of adherent patients in the pre-period was assumed to 0.182, 0.333 
and 0.415 (Ps) for Thiazolidinediones, Biguanides and Sulfonylureas respectively and 
proportion of adherent patients in the post period is assumed to be 0.8199 (Pt).  The 
26 
 
proportion of discordant pairs (PD) was 0.7034564, 0.6068466 and 0.554383 and odds ratio 
was 4.504945055, 2.462162162 and 1.975662651 for Thiazolidinediones, Biguanides and 
Sulfonylureas respectively (calculated using the formulas listed above). Using these values 
and alpha level of 0.05 and a power of 0.80; 19, 58 and 109 pairs were required to perform 
the original McNemar’s Test. Taking these sample sizes into consideration, a conservative 
estimate of 109 pairs was required for the purpose of analysis of oral diabetes medications 
drug class. 
 Hypertension medications including ACEs/ARBs: According to the performance scores 
calculated on the Mississippi Medicare data for the year 2007, approximately 40.00% 
patients (18 years and older) were found to be adherent (meeting PDC threshold of 80%) to 
hypertension medications (ACEI/ARBs). According to guidelines given by the CMS Star 
Rating system under the PDP, a pharmacy needs to have percentage of adherent patients 
between ≥ 76% and < 81% in order to achieve 3 stars in the CMS Star Rating system. For 
the purpose of this analysis the proportion of adherent patients in the pre-period was 
assumed to be 0.40 (Ps) and proportion of adherent patients in the post period was assumed 
to be 0.8099 (Pt).  The proportion of discordant pairs (PD), i.e., 0.56198 and odds ratio, i.e., 
2.02475 was calculated using the formulas listed above. Using these values and alpha level 
of 0.05 and a power of 0.80; 95 pairs were required to perform the original McNemar’s Test. 
 Cholesterol medications including statins: According to the performance scores calculated 
on the Mississippi Medicare data for the year 2007, approximately 28.90% patients (18 years 
and older) were found to be adherent (meeting PDC threshold of 80%) to cholesterol 
medications (statins). According to guidelines given by CMS Star Rating system under the 
PDP, a pharmacy needs to have percentage of adherent patients between ≥ 69% and < 75% 
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 in order to achieve 3 stars in the CMS Star Rating system. For the purpose of this analysis 
the proportion of adherent patients in the pre-period was assumed to be 0.289 (Ps) and the 
proportion of adherent patients was assumed to be 0.7499 (Pt). The proportion of discordant 
pairs (PD), i.e., 0.6 and odds ratio, i.e., 2.6was calculated using the formulas listed above. 
Using these values and alpha level of 0.05 and a power of 0.80; 50 pairs were required to 
perform the original McNemar’s Test.  Calculations for the original McNemar’s Test are 
provided in Table 3 below:  
 
Table 3: Sample Size Calculation for McNemar’s Test 
 Post 
Period 
(Pt) 
Pre 
Period 
(Ps) 
Proportion 
of 
Discordant 
Pairs (PD) 
Odds 
Ratio 
Alpha Power Total 
Sample 
Size (N= 
# of pairs) 
        
Diabetes  0.8199 0.415 0.554383 1.98 0.05 0.80 109 
Hypertension  0.8099 0.40 0.56198 2.02 0.05 0.80 95 
Cholesterol  0.7499 0.289 0.6054578 2.60 0.05 0.80 50 
 
Data collection 
Study investigators visited the pharmacies to collect data for this study. A DUA was 
executed between each pharmacy and the University of Mississippi before data collection. All 
the prescription fill data was transferred from the computer system to a flash memory drive. As 
soon as the data was collected, the patient identifiers were converted into a de-identified format 
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by encrypting the patient identifiers assigned by the pharmacy. All Data File(s) were 
installed on a secure, stand-alone, non-networked access computer maintained in the School of 
Pharmacy, housed in a secure Center for Pharmaceutical Marketing and Management (CPMM) 
Data Center. The study was approved by the Institutional Review Board (IRB) of The University 
of Mississippi. 
Data management 
All the pharmacy data was pulled, cleaned, processed and analyzed with the help of 
Statistical Analysis Software 9.4 (SAS®, SAS Institute, Cary, NC). Based on the National 
Drug Code (NDC) of the drugs; prescription records were assigned to their respective therapeutic 
classes as classified by CMS Star Rating system. Detailed list of all the drugs with their NDCs, 
which are included in the PQA Measure of Proportion of Days Covered (PDC) for oral diabetes 
medications, hypertension medications and cholesterol medications was used for the purpose of 
this study. All the original collected data was stored on the secured server in order to maintain 
the security and privacy of the data and participating individuals.  Patient identifiers were 
converted into an encrypted format by de-identifying the patient identifiers. Later in the analysis, 
patients were identified in the pharmacy database with their help of their de-identified patient 
identifiers. Patients were identified as a part of the med sync program with the help of their index 
date specified by the pharmacist. 
Measures 
Proportion of days covered (PDC) was used to calculate the adherence of patients in 
the study. PDC is the preferred measure of adherence by the PQA. The mathematical 
formula PDC is given as below: 
PDC = Number of days the patient is covered by the drug in the study period 
Number of days in the study period 
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PDC helps to achieve a conservative estimate of the medication adherence especially when 
a patient consumes more than one medication for their treatment. Considering the current 
study focusing on med sync, whereby the patients of interested consumer more than one 
chronic prescription drug per month; the use of PDC as an adherence measurement became 
more relevant. PDC is always helpful in adjusting for the gaps in therapy and also 
adjusting for overlap in therapy. While doing the calculations for PDC, a day is only 
counted if the patient has medication in his or her possession. PDC values can range from 
zero to one. The assumption that we make while using such a measure, is that, when a 
medication is possessed the medication is assumed to be consumed as well.26 Patients 
having PDC equal to or greater than 0.80 were considered adherent. According to the 
measure, if multiple prescriptions for the same generic drug are given on the same day or 
different days with overlapping days’ supply, adjustment should be made to the 
prescription start date, so that the start date for the same second generic drug is  the day 
after the previous fill has ended. Same adjustment was performed while calculating the 
PDCs for the study participants. 
Data analyses 
Data analysis was conducted using SAS software (version 9.4; SAS Institute, Cary, NC). 
Descriptive statistics of the sample after applying inclusion-exclusion criteria were calculated 
for each of the therapeutic drug classes separately. Descriptive statistics included calculating 
means, frequencies and percentages as appropriate. 
For assessing study objectives, PDC scores for the pre and post periods for each patient in 
the study were calculated. Patients having a PDC value of 0.80 or more were considered 
“adherent” and PDC less than 0.80 were considered “non-adherent”.  A dichotomous flag 
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variable was created, in which adherent patients will be flagged as “1” and non-adherent patients 
were flagged as “0”.  Because this study uses a pre-post design, patients served as their own 
control.  Patients’ PDC values before and after the index date were calculated. Mean and median 
PDC scores of pre and post periods for each of the three CMS drug classes were obtained.  
Considering the paired nature of the observations and non-normality of the PDC scores 
(proportion), Wilcoxon Signed-Rank Test for paired data was used to compare the PDC scores of 
pre and post periods for each of the three drug classes separately.  An alpha level of 0.05 was 
used for the Wilcoxon Signed-Rank Test for the paired data, obtaining a p-value lesser than 0.05 
lead to the rejection of the null hypothesis helping us to infer that the pre-period and post-period 
scores are statistically different from each other.  Secondly, the proportion of adherent patients in 
the pre-period was compared to the proportion of adherent patients in the post-period for each of 
the three therapeutic drug classes separately. In order to calculate this proportion, the numerator 
included all those patients meeting the inclusion/exclusion criteria and flagged as “1”. Whereas, 
the denominator included all those patients meeting the inclusion/exclusion criterions and 
flagged as “1” or “0” both. An alpha level of 0.05 was used for this test, obtaining a p-value 
lesser than 0.05 lead to the rejection of the null hypothesis and helped us to infer that the 
marginal proportions are significantly different from each other.  After performing the 
McNemar’s Exact Test a 2x2 contingency table was obtained to calculate the odds of adherence 
in the post-period as compared to the pre-period. McNemar’s Exact Test was performed for each 
of the three drug classes separately.
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RESULTS 
Sample description 
Prescription transaction data was collected from Thrift Drugs, Gene Polk’s Pharmacy, 
Tyson Drugs Co and Iuka Discount drugs. An initial list of total 126, 139 and 146 synchronized 
patients containing index date and enrollment date information was obtained from Gene Polk’s 
Pharmacy, Tyson Drugs Co and Iuka Discount drugs pharmacy respectively. Due to the 
unavailability of index date and enrollment date information at Thrift Drugs Pharmacy, all of 
their prescription transaction data was discarded and Thrift Drugs pharmacy was excluded from 
the study. Data from the remaining three pharmacies was combined and patients were assigned 
to their respective drug classes by matching the NDC numbers present in their prescription 
transaction records with the list of the NDCs provided by PQA for each of their drug classes. 
Multiple patients contributed to more than one drug class considering that many of them 
were taking multiple drugs belonging to more than one drug category. Separate datasets were 
created for diabetes, hypertension and cholesterol categories. Inclusion and exclusion criteria 
were applied to each of the drug categories separately for the purpose of analysis. 
A total of 56, 89 and 77 patients were found to meet the inclusion/exclusion criteria in 
diabetes, hypertension and cholesterol drug categories, respectively. The average age of the 
patients was approximately 66 years (23-87 years, ± 11.03), 70 years (41-101 years, ± 11.53) and 
67 years (40-100 years, ± 11.85) in diabetes, hypertension and cholesterol drug categories, 
respectively. The sample predominantly belonged to those patients who were falling in the age 
category of 60-80 years (Table 4).
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Patient PDC values 
Using the prescription transaction data, proportion of days covered (PDC) was calculated 
for the pre-period and post-period. Each patient had a unique index date, and depending upon 
that index date, their own pre-period and post-period. The results indicate that 47 (83.93%), 67 
(75.28%) and 59 (76.62%) patients belonging to the diabetes, hypertension and cholesterol drug 
categories, respectively, had PDC values in the range of 90-100 in the pre-period. Whereas in the 
post-period, almost 54 (96.43%), 87 (97.75%) and 74 (96.1%) patients belonging to diabetes, 
hypertension and cholesterol drug categories, respectively, had PDC values in the range of 90-
100. Results indicate an appreciable increase in the number of patients whose PDC values were 
in the range of 90-100. A full description of the distribution of patients falling in various PDC 
categories are presented in Table 5. 
 
Table 4:  Distribution of Patients by Age 
Age Categories Diabetes (%) Hypertension (%) Cholesterol (%) 
    
18-40 1 (1.79) 0 0 
40-60 8 (14.29) 13 (14.61) 19 (24.68) 
60-80 43 (76.79) 59 (66.29) 48 (62.34) 
80-100 4 (7.14) 15 (16.85) 9 (11.69) 
100+ 0 2 (2.25) 1 (1.30) 
Total 56 (100) 89 (100) 77 (100) 
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Patients PDC values categorized by age 
A cross-table was also created between age categories and PDC categories in the pre-
period as well as the post-period. This information is provided in Table 6 below for diabetes, 
hypertension and cholesterol drug categories, respectively. A majority of the patients were 
between 60 and 80 years and had PDC values ranging from 90 to 100 during both the periods in 
all the three drug categories. 
 
 
 
 
 
Table 5:  Distribution of Patients Belonging to PDC Categories in Pre- and Post-Period 
 Proportion of Days Covered (PDC) Categories 
 30-40 
(%) 
40-50 
(%) 
50-60 
(%) 
60-70 
(%) 
70-80 
(%) 
80-90 
(%) 
90-100  
(%) 
        
Diabetes        
Pre-Period 1 (1.79) 1 (1.79) 1 (1.79) 1 (1.79) 1 (1.79) 4 
(7.14) 
47 
(83.93) 
Post-Period 0 0 0 0 0 2 
(3.57) 
54 
(96.43) 
        
Hypertension        
Pre-Period 0 0 4 (4.49) 3 (3.37) 2 (2.25) 13 
(14.61) 
67 
(75.28) 
Post-Period 0 0 0 0 1 (1.12) 1 
(1.12) 
87 
(97.75) 
        
Cholesterol        
Pre-Period 0 0 3 (3.9) 2 (2.6) 2 (2.6) 11 
(14.29) 
59 
(76.62) 
Post-Period 0 0 0 0 1 (1.3) 2 (2.6) 74 
(96.10) 
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Table 6:   Patient PDC Values Categorized by Age 
 Age Categories 
 18-40 (%) 40-60 (%) 60-80 (%) 80-100 (%) 100+ (%) 
      
Diabetes      
Pre-Period      
30-40 0 0 1 (1.79) 0 0 
40-50 0 0 1 (1.79) 0 0 
50-60 0 0 1 (1.79) 0 0 
60-70 0 0 1 (1.79) 0 0 
70-80 0 0 1 (1.79) 0 0 
80-90 0 1 (1.79) 3 (5.36) 0 0 
90-100 1 (1.79) 7 (12.50) 35 (62.50) 4 (7.14) 0 
      
Post-Period      
80-90 0 1 (1.79) 1 (1.79) 0 0 
90-100 1 (1.79) 7 (12.50) 42 (75) 4 (7.14) 0 
      
Hypertension      
Pre-Period      
50-60 0 0 2 (2.25) 2 (2.25) 0 
60-70 0 1 (1.12) 1 (1.12) 1 (1.12) 0 
70-80 0 0 2 (2.25) 0 0 
80-90 0 0 13 (14.61) 0 0 
90-100 0 12 (13.48) 41 (46.07) 12 (13.48) 2 (2.25) 
      
Post-Period      
70-80 0 0 1 (1.12) 0 0 
80-90 0 0 1 (1.12) 0 0 
90-100 0 13 (14.61) 57 (64.04) 15 (16.85) 2 (2.25) 
      
Cholesterol      
Pre-Period      
50-60 0 2 (2.60) 1 (1.30) 0 0 
60-70 0 0 1 (1.30) 1 (1.30) 0 
70-80 0 0 2 (2.60) 0 0 
80-90 0 4 (5.19) 5 (6.49) 1 (1.30) 1 (1.30) 
90-100 0 13 (16.88) 39 (50.65) 7 (9.09) 0 
      
Post-Period      
70-80 0 1 (1.30) 0 0 0 
80-90 0 1 (1.30) 1 (1.30) 0 0 
90-100 0 17 (22.08) 47 (61.04) 9 (11.69) 1 (1.30) 
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Comparing PDC values between the pre-period and post-period 
The objective for this study was to compare the mean PDC values of the patients in pre-
period with their PDC value in the post-period. 
Wilcoxon Signed-Rank Test: PDC values were calculated for the pre-period and post 
period for each patient. A variable was created by subtracting the post-period PDC values from 
the pre-period PDC values for each patient. Considering the paired nature of the observations 
and non-normality of the PDC scores (proportion), a Wilcoxon Signed-Rank Test for paired data 
(alpha= 0.05) was performed separately for each of the drug categories. 
Diabetes: An average PDC of 94 ± 0.14 and 99 ± 0.03 was found in the pre-period and 
post-period respectively. As a result of this analysis, a Wilcoxon-Signed Rank Test statistic of 
143 (p= 0.0001) was obtained. The required sample size for this analysis was 82 patients 
whereas the current study had only 56 patients. Therefore sample size requirements were not met 
for this test. 
Hypertension: An average PDC of 94 ± 0.12 and 99 ± 0.03 was found in the pre-period 
and post-period respectively. As a result of this analysis, a Wilcoxon-signed rank test statistic of 
391 (p= <.0001) was obtained. 
Cholesterol: An average PDC of 94 ± 0.11 and 99 ± 0.04 was found in the pre-period and 
post-period respectively. As a result of this analysis, a Wilcoxon-signed rank test statistic of 
369.5 (p= <.0001) was obtained. The required sample size for this analysis was 82 patients 
whereas the current study had only 77 patients. Therefore sample size requirements were not met 
for this test. 
The two-tailed p-values generated by the Wilcoxon-Signed Rank Test for each of the 
three drug categories was less than 0.05. Therefore, the null hypothesis was rejected and it is 
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concluded that statistically significant differences exist between the PDC values in pre-period 
and PDC values of post-period for all the drug categories. Results of this analysis are shown in 
detail in Table 7. 
 
*Significant at α = 0.05 
 
Comparison between proportions of adherent patients in pre-period and post period 
In a secondary analysis, the proportion of adherent patients in pre-period was compared 
to the proportion of adherent patients in post-period. Adherent patients were those who had a 
PDC value greater than or equal to 0.80 and were flagged as ‘1’ and non-adherent patients were 
flagged as ‘0’. In order to calculate this proportion, the numerator included all those patients 
meeting the inclusion/exclusion criteria and flagged as “1”. Whereas, the denominator included 
Table 7: Wilcoxon-Signed Rank Test Results 
Drug Class Pre-Period Post-Period Wilcoxon-Signed 
Rank Statistic (S) 
P (Two-tailed) 
 Mean (Standard 
Deviation) 
Mean (Standard 
Deviation) 
  
     
Diabetes 0.94 (0.14) 0.99 (0.03) 143 0.0001* 
Hypertension 0.94 (0.12) 0.99 (0.03) 391 <.0001* 
Cholesterol 0.94 (0.11) 0.99 (0.04) 369.5 <.0001* 
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all those patients meeting the inclusion/exclusion criterions and flagged as “1” or “0” both. In 
order to meet this research objective, McNemar’s Exact Test was performed separately for each 
of the drug categories. 
A McNemar’s Exact Test was conducted rather than the original McNemar’s Test to 
account for the small sample size employed in the study. This was also done keeping in mind 
that, the sum of discordant pairs in all the drug categories were less than 25 i.e. b+c< 25. A 2x2 
contingency table was obtained as a result of this analysis and odds ratios with confidence 
intervals ranging from 5% to 95% were also obtained. Odds ratio results signified the odds of 
adherence (depending upon the drug class) in post-period as compared with pre-period. 
McNemar’s Exact Test results are described below by drug category. 
Diabetes: The required sample size for this analysis was 109 patients whereas the current 
study had only 56 patients, therefore, sample size requirements were not met.   The results of 2x2 
contingency table after performing the McNemar’s Exact Test (Table 4) suggests that there were 
51 (91.07%) adherent patients in pre-period whereas there were 56 (100%) adherent patients 
post-period. The test performed also yielded an exact p-value equal to 0.0625, greater than alpha 
0.05. Using the results, the null hypothesis is not rejected. Therefore it can be concluded that 
although there was an increase in the proportion of adherent patients from pre-period to post-
period, the difference in the proportion was not statistically significant. 
The odds ratio of being adherent in post period as compared to pre-period was equal to 
infinity. This can be attributed to the fact that no one who was adherent in the pre-period stayed 
non-adherent in the post-period and no one who was adherent in pre-period became non-adherent 
in the post-period. In this situation one of the discordant pairs was zero, leading to an odds ratio 
equal to infinity. The odds ratio of infinity has a 95% CI ranging from 0.05 to infinity because in 
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a case when OR equal to infinity, the upper exact confidence limit is set to infinity and the lower 
limit is set to alpha, which is 0.05 for the current study. Therefore it can be concluded that there 
was large difference between the proportions of adherent patients in post-period as compared 
pre-period, however the difference was not statistically significant. Results of McNemar’s Exact 
Test for diabetes drug category is shown in Tables 8 and 11. 
 
 
 
 
 
 
 
 
Hypertension: The required sample size for this analysis was 95 patients whereas the 
current study had only 89 patients, therefore sample size requirements were not met. A total of 
80 (89.89%) patients were adherent in the pre-period as compared to 88 (98.88%) patients in the 
post-period. The test performed yielded an exact p-value of 0.0215, less than alpha 0.05. Using 
these results, the null hypothesis is rejected and it is concluded that the difference in the 
proportion of adherent patients in pre-period and post-period is statistically significant. 
When evaluating the odds of adherence, patients in the post-period had a 9 times higher 
odds of adherence as compared to pre-period. Results of the McNemar’s Exact Test for the 
hypertension drug category is shown in Tables 9 and 11. 
 
Table 8:  2x2 Contingency Table for Diabetes 
 Post-Period 
Pre-Period Non-Adherent (%) Adherent (%) 
Non-Adherent 0 5 (8.93) 
   
Adherent 0 51 (91.07) 
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Cholesterol: A total of 70 (90.91%) patients were adherent in the pre-period as compared 
to 76 (98.70%) patients in the post-period. The test performed yielded an exact p-value equal to 
0.0703 greater than alpha 0.05. Using the results, the null hypothesis is not rejected. Therefore it 
is concluded that although there was an increase in the proportion of adherent patients from pre-
period to post-period, the difference in the proportion was not statistically significant. 
When evaluating odds of adherence, patients in the post-period had a 7 times higher odds 
of adherence compared to the pre-period. Results of the McNemar’s Exact Test for the 
cholesterol drug category is shown in Tables 10 and 11. 
 
 
 
 
 
 
 
  
Table 9:  2x2 Contingency Table for Hypertension 
 Post-Period 
Pre-Period Non-Adherent (%) Adherent (%) 
Non-Adherent 0 9 (10.11) 
   
Adherent 1 (1.12) 79 (88.76) 
Table 10: 2x2 Contingency Table for Cholesterol 
 Post-Period 
Pre-Period Non-Adherent (%) Adherent (%) 
Non-Adherent 0 7 (9.09) 
   
Adherent 1 (1.30) 69 (89.61) 
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 In the pre-period, approximately 89.89% to 91.07% patients were considered adherent 
depending upon the drug category. Whereas, the proportion of adherent patients ranged from 
98.70% to 100% in the post period depending upon the drug category. Table 8 contains all the 
results derived from the McNemar’s Exact Test for all the three drug categories. 
*Significant at α = 0.05
Table 11.  Results of McNemar’s Exact Test 
 Adherent Patients 
(%) 
    
Drug Class Pre-
Period 
Post-
Period 
Odds Ratio (CI) Change in 
Proportion 
DF P 
(Two-Tailed) 
       
       
Diabetes 51 
(91.07) 
56 
(100) 
0.05-Infinity 8.93 1 0.0625 
Hypertension 80 
(89.89) 
88 
(98.88) 
9 
(1.14-71.04) 
8.99 1 0.0215* 
Cholesterol 70 
(90.91) 
76 
(98.70) 
7 
(0.86-56.89) 
7.79 1 0.0703 
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DISCUSSION 
This study aimed to explain the impact of medication synchronization (med sync) on 
medication adherence. Adherence plays a crucial role in the Centers for Medicare and Medicaid 
Services’ (CMS) Star Rating System which is designed to assist Medicare beneficiaries in plan 
selection. Among the five measures used by CMS and Pharmacy Quality Alliance (PQA) for 
calculating the Star Rating, three of them are related to the medication adherence.3,7 From a 
clinical perspective, adherence is vital to attain the therapeutic effect of medication therapy, so it 
is critical to understand the importance of med sync program in improving the medication 
adherence of patients.  
A quasi-experimental pre-post study design was employed for this study using pharmacy 
prescription fill data from various independent community pharmacies located in different 
regions of Mississippi.  Patients were compared on the main outcome measure, medication 
adherence, before and after the medication synchronization intervention. Because this study 
employed a pre-post study design, patients served as their own control. Drug classes in the CMS 
Five-Star Quality Rating System that were examined include oral diabetes medications, 
hypertension medications and cholesterol medications. Data was utilized from three different 
pharmacies located in different regions of Mississippi. 
Discussion of findings 
The only demographic information available for patients in this study was age. Most 
patients were between 60 and 80 years old. Similar age trends were noted in an evaluation of 
another med sync program conducted by Holdford et al.1 This is in line with the expectation that 
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older patients utilize more prescription medications than younger patients, and therefore are 
potentially better candidates for a med sync program.27  
Because average PDC values in the post-period were higher than average PDC values in 
the pre-period, it is evident that the medication adherence improved after being enrolled in the 
med sync program. After performing Wilcoxon Signed-Rank Tests, it was found that the 
improved adherence was statistically significant in all three drug categories. It is worth noting 
here, however, that pre-period adherence values were exceptionally higher than the investigators 
expected. For example, average pre-period PDCs for all drug categories was 0.94, increasing to 
0.99 after med sync was implemented. It is possible that patients who were most adherent, and 
thus being more present in the pharmacy for their refills and engaged in their own care, were not 
only perceived as needing med sync more, but also easier to recruit into the program, thus 
resulting in self-selection bias into the med sync program. Meaning that, patients in this study 
may not have been representative of typical patients in each of these pharmacies. 
After finding that the PDC values between the pre-period and post-period significantly 
improved, a follow up analysis was conducted to confirm these findings. For this purpose, the 
proportion of adherent (PDC ≥ 0.80) patients in the pre-period and post-period was calculated. 
Upon the formulation of a 2x2 contingency table the McNemar’s Exact Test for small sample 
sizes (where the sum of discordant pairs were less than 25) was performed. For oral diabetes 
medications, an increase of approximately 8.93% adherent patients from pre-period to post-
period was noticed. However, this increase in the proportion of adherent patients was not 
statistically significant.  
Lack of a statistically significant change could be attributed to the small sample size for 
this drug category and presence of too much ‘noise’ in the data. The small sample for this study 
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can be explained by the fact that our sample largely consisted of adults between 60 and 80 years 
of age. In fact, four out of 56 in the diabetes medication category were between 80 and 100 years 
old. It is likely that older diabetes patients are being treated with insulin after first-line oral 
diabetic treatments used in the earlier stages of their disease. From a clinically practical 
standpoint, however, it is impressive to note that 91% of patients were considered adherent prior 
to the intervention, while 100% were considered adherence after the intervention. So while not a 
statistically significant change, adherence in more than 100% of patients cannot be obtained. 
Again, the fact that 91% of patients were adherent prior to the intervention may be reflective of a 
biased sample. 
In the hypertension category, there were 80 (89.89%) adherent patients in the pre-period 
whereas there were 88 (98.88%) adherent patients post-period. As consistent with the direction 
of the previously stated hypothesis, an increase of approximately 8.99% adherent patients from 
pre-period to post-period was noticed. Despite a small sample and underpowered test, 
statistically significant improvements were still detected.  
As with diabetes medications, the increase in the proportion of patients adherent to 
cholesterol medications was not statistically significant. Looking again from a clinical 
perspective, nearly 91% of patients were considered adherent prior to the intervention, while 
nearly 99% were considered adherence after the intervention. So again, while not a statistically 
significant change, practically speaking, having nearly 99% of patients adherent to their 
cholesterol medications is would be all accounts be considered reasonable in the practice setting. 
Limitations 
The study contains several limitations. The findings of current study may not be 
generalizable to a national population considering that this data was acquired from community 
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pharmacies located in Mississippi. The literature suggests that pharmacists can influence 
medication adherence, and each pharmacy will likely have its own impact on medication 
adherence, which was not controlled in this study.1 The study also did not control for risk factors 
impacting adherence such as general comorbidities of patients, individual risk factors associated 
with respective drug categories, health insurance status, race, gender, severity of disease 
conditions, patients’ motivation to be enrolled in med sync. Also, the findings from the current 
study will merely reflect the association between adherence and med sync and does not imply 
causality. 
We were unable to identify exact index dates for each patients due to documentation 
issues in the pharmacies. Therefore, an estimate of the index dates was taken using available 
information such as enrollment dates and monthly prescription dispense dates. An algorithm for 
index date selection was used, such that the index date was the date after the enrollment date 
upon which the patient received multiple monthly prescriptions on the same date for at least 
three months. 
Sample size requirements were not met for the diabetes and hypertension drug categories 
for McNemar’s Exact Tests and sample size requirements were not met for diabetes and 
cholesterol drug categories for the Wilcoxon Signed-Rank Tests, making these tests 
underpowered. Upon discussion with the pharmacists, it was found that the med sync program 
offered in the pharmacies was an opt-in program in which the patients must consent to be 
enrolled in the program once the offer to join the program is made by the pharmacist. This can 
lead to self-selection bias because patients in the med sync program might be more engaged in 
their own health relative to other patients who chose not to enroll in the program. Not 
surprisingly, upon conversations with pharmacists, it was found that patients visiting the 
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pharmacy multiple times a month for refills were considered the best candidate for med sync. 
Although recruiting these patients is consistent with the objectives of med sync, simultaneously, 
it also creates a pharmacy-selected pool of patients who are highly enthusiastic about 
maintaining their health leading to a possible bias in the study. 
Another challenge in this study was that, each of the pharmacies had different types of 
pharmacy management software which can lead to discrepancies in the data overall. Also, using 
PDC as an adherence measure assumes that if medication is possessed, it is consumed as well. In 
reality, this might not be the case. Additionally, patients who were excluded from the study due 
to a 90 day or more gap between fills might have not actually been non-persistent, but instead 
might have switched pharmacies or been advised by the prescriber to discontinue taking their 
medication. Considering the nature of the study as well as the nature of the pharmacy 
prescription transaction data used, it was outside the scope of this study to address these latter 
limitations. 
Directions for future research 
This study evaluated how med sync can potentially improve medication adherence of 
patients by employing a quasi-experimental pre-post study design by utilizing pharmacy 
prescription transaction data collected from independent communities situated in various regions 
of Mississippi. Moving forward, studies evaluating similar objectives should employ a 
randomized case control design. This will help to control for the self-selection bias that can occur 
when patients are approached about enrollment in med sync. Self-selection bias can lead to the 
enrollment of those patients who were motivated to improve their adherence already and can 
result in inflated PDC results both before and after a med sync intervention. 
48 
 
Also, considering the nature of prescription transaction data and the unavailability of the 
important risk factors that need to be controlled, a survey research could be used to supplement 
the secondary data evaluation of med sync on medication adherence. This may help researchers 
extract valuable information from the patients which is otherwise difficult to obtain from a 
pharmacy dispensing database.  
 Researchers conducting similar studies in the future should ensure consistent, controlled, 
and structured med sync programs. In particular there should be adequate and accurate 
documentation. Ideally, a dedicated researcher proficient with the process of medication 
synchronization should be appointed in the pharmacy to manage the program. Creating a 
comprehensive documents containing the guidelines to conduct med sync program should be 
created and should be followed strictly while implementing the program. Most importantly, 
future researchers should assure that med sync programs are adjusting refills based on patient-
reported adherence, not just refilling a month’s worth medication, assuming that they patient has 
been perfectly adherent. Doing the latter results in inflated adherence rating, and may be 
considered fraud by stakeholders reimbursing pharmacists for good adherence rates. 
 The convenience that comes with med sync for pharmacy patients is a relatively 
unexplored area. Not only are patients profoundly reducing the number of visits they make to the 
pharmacy, but their medication is already available in the pharmacy when they visit. Most 
importantly, med sync should allow for increased pharmacist contact and attention due to 
streamlined workflow. In theory, it can be assumed that all of this would lead to patient 
satisfaction. Future studies should aim at exploring such non-clinical benefits, or even health-
related quality of life as a result of the med sync. These kind of assessments are of utmost 
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importance for third parties who may be paying pharmacists for such interventions and to 
maintain emphasis on a patient centric model. 
 Better inventory management, streamlined work flow, and less walk-in traffic are some 
of the benefits that a pharmacy receives when practicing med sync program. Considering that the 
pharmacist has a critical role to play in the program, the attitudes and satisfaction level of the 
pharmacist derived from a med sync program should also be assessed in future studies. 
 With scheduled monthly visits by the patients purchasing multiple prescription 
medications for the month, there is an expected increase in the revenue for the pharmacy. At the 
same time, there in a decrease in the overall walk-in visits which might would lead to a decrease 
in the upfront sales. A study in the future, evaluating the net benefit of this program might would 
help the pharmacy to understand med sync benefits from a monetary perspective. 
 Upon discussion with the pharmacist, it was found that pharmacies adjust the upcoming 
prescription’s days of supply if a patient has not been adherent in the previous month or have 
missed few doses. Although they pay the same amount of co-pay associated with the drug they 
sometimes receive lesser quantity of doses depending upon their consumption in the last month. 
Some patients were not in favor of this and left the program because they did not wish to pay the 
same amount of co-pay and receive lesser drug quantity. From this we can infer that co-pay or 
co-insurance has an important role to play in the med sync program, therefore future studies 
should aim at exploring this issue in detail. 
 In exploring the core issue of the current study, improving adherence is most salient to 
stakeholders of med sync, particularly payers. There is a wealth of literature demonstrating 
positive intermediate and other clinical outcomes as a function of medication adherence. Linking 
improved adherence as a result of med sync with health outcomes should be a priority of future 
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med sync research, and will inevitably become a necessity for payers considering reimbursing 
pharmacies for such services. In addition to linking med sync to health-related outcomes, 
research should attempt to link med sync with health costs related to emergency room visits or 
hospitalizations. A detailed cost analysis could be performed by linking synchronized patients to 
Medicaid and other claims databases.  
Conclusion 
This is the first study to assess the impact of medication synchronization on medication 
adherence while employing a quasi-experimental pre-post study design by utilizing the pharmacy 
prescription transaction data from various independent community pharmacies in Mississippi. 
The results indicated that after being enrolled in med sync, medication adherence generally 
improves. When linked to literature that correlates adherence with positive health and economic 
outcomes, med sync programs can offer potential benefit to the healthcare system.  
An important stakeholder in med sync is Centers of Medicare and Medicaid Services’ 
(CMS) because they evaluate Medicare Part D plans on the basis of Star Rating system which is 
useful in making quality based payments to Medicare Advantage Plans (MA-PDs), selling 
benefits of prescription drug plans (PDPs) and assisting Medicare beneficiaries in plan selection. 
Results of this study and similar ones conducted in future will become even more important with 
the boom of commercial Part D plans making it necessary to monitor the adherence and 
subsequent health outcomes.
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Meeting, Montreal, QC, Canada. (June 2014) 
 
MASTER’S THESIS:  
 “Impact of refill synchronization on medication adherence for chronic diseases” 
(December 2015) 
 
CLASS PROJECTS:  
 Health Economics: “Impact of attention deficit hyperactivity disorder (ADHD) and its 
treatment on missed school days among school going children (5-17 years) in United 
States using MEPS database” 
 Pharmaceutical and Healthcare Policy: ”Medication synchronization using appointment 
based model—A commentary” 
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 Pharmacoeconomics: ”A Markov cost-effectiveness model comparing fluticasone 
propionate/salmeterol combination (SFC) and mometasone furoate/formoterol fumarate 
dehydrate (MF) in the management of asthma” 
 Primary Data Techniques: “Perceptions of employees on expanding employee health 
services at the university” -- Focus groups and questionnaire development 
 Research Methods: “Short term impact of environmental supports (CAT, GES, and 
Pharm-CAT) on cognitive functioning and medication adherence in outpatients with 
schizophrenia: A proposal” 
 Secondary Data Techniques: “Developing algorithms for identifying beneficiaries with 
higher than expected utilization of opioid analgesics -- Mississippi Medicaid Database” 
  
AWARDS:  
 University of Mississippi Graduate School Travel Grant for attending the ISPOR 19th 
Annual International Meeting, Montreal, QC, Canada, June, 2014 
 University of Mississippi Graduate School Travel Grant for attending the ISPOR 20th 
Annual International Meeting, Philadelphia, PA, May, 2015  
 
SERVICE:  
 Secretary, ISPOR – Student Chapter, University of Mississippi (2015 - 2016)  
 Student Member, ISPOR (August 2013 - December 2015)  
 The Rho Chi Society – An Academic Honor Society in Pharmacy (February 2015 - 
December 2015) 
 
LICENSES: 
 Registered pharmacist, New Delhi, India 
